---
type: 
up: 
down: 
related: 
tags: []
dg-publish: true
title: CC_TOX
date created: Friday, March 7th 2025, 00:09:03
date modified: Tuesday, March 25th 2025, 16:09:20
---

CICM - "An understanding of potential toxicity and relevant antidotes is also expected."

- [[ANZCA.4.2.5_BT_GS.1.34_Flumazenil_Pharmacology_and_Use|Flumazenil]]
- [[ANZCA.13.2.9_BT_RT.1.19_Dantrolene_Pharmacology_Malignant_Hyperthermia|Dantrolene]]
- [[CICM.GP3.xi - Digoxin Antibodies (L3)|Digibind]]
- [[CICM.KP3.xiii - Local Anaesthetics Reversal - Intralipid (L3)|Intralipid]]
- [[CICM.KP3.xiv - Opioid Reversal - Naloxone (L3)|Naloxone]]
- [[CICM.LP3.ii - Sugammadex (L3)|Sugammadex]]
- [[CICM.MP3.i - Pralidoxime (L3)|Pralidoxime]]
- [[CICM.NP3.i - N-acetylcysteine (L3)|NAC]]
- [[CICM.QP3.i - Anticoagulant Reversal Agents (L3)|Anticoag Reversal]]
